mug109 Antibody

What is the MUC1 antibody and what epitopes does it recognize?

The MUC1 antibody [EPR1023] (ab109185) is a recombinant rabbit monoclonal antibody developed using patented technology that specifically recognizes and binds to the MUC1 protein. This antibody has been validated against wild-type MUC1 protein, with specificity confirmed through knockout validation experiments in which the antibody signal was lost in MUC1 knockout cells .

The antibody recognizes specific epitopes on the MUC1 protein. While the exact epitope binding region isn't specified in the available data, Western blot analysis shows the antibody detects bands at 17-24 kDa in wild-type HeLa cell lysates and a 24 kDa band in colon cancer samples, despite the predicted full-length MUC1 protein size being approximately 122 kDa . This suggests the antibody may be recognizing a specific processed fragment or glycoform of the MUC1 protein.

What applications has the MUC1 antibody been validated for?

The MUC1 antibody [EPR1023] (ab109185) has been validated for multiple research applications:

• Western blotting (WB)

• Immunoprecipitation (IP)

• Immunohistochemistry on paraffin-embedded sections (IHC-P)

• Immunocytochemistry/Immunofluorescence (ICC/IF)

• Flow cytometry (intracellular) (Flow Cyt (Intra))

The antibody has been tested and confirmed to work with human, mouse, and rat samples . This multi-application validation makes it versatile for different experimental approaches when studying MUC1 expression and function.

How should knockout validation be interpreted when evaluating antibody specificity?

Knockout validation is considered a gold standard for confirming antibody specificity. In the case of the MUC1 antibody (ab109185), wild-type and MUC1 knockout HeLa cell lysates were subjected to SDS-PAGE and Western blot analysis. The antibody showed clear detection of bands in wild-type cells, while the signal was absent in the knockout cells .

When interpreting knockout validation data, researchers should:

• Confirm the complete absence of signal in the knockout samples using appropriate controls (such as GAPDH, which should be present in both wild-type and knockout samples)

• Verify that the detected band size aligns with expectations for the target protein or its known processed forms

• Consider that some antibodies might recognize specific post-translational modifications or conformational epitopes that could affect detection patterns

• Evaluate whether the validation was performed in relevant cell types or tissues for your specific research question

The MUC1 antibody validation used GAPDH as a loading control (detected with a mouse anti-GAPDH antibody), confirming equal protein loading across samples and strengthening the reliability of the specificity assessment .

What are the optimal conditions for using MUC1 antibody in Western blotting?

Based on the validation data, the following conditions have been established as optimal for using the MUC1 antibody [EPR1023] (ab109185) in Western blotting:

• Antibody dilution: 1/1000 has been shown to be effective

• Blocking buffer: 5% non-fat dry milk (NFDM) in TBST

• Dilution buffer: 5% NFDM in TBST

• Secondary antibody options:

  • Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) at 1/20000 dilution for fluorescent detection

  • Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution for chemiluminescent detection

• Sample loading: 20 μg of whole cell lysate is typically sufficient for detection

• Expected band size: While the predicted size of full-length MUC1 is 122 kDa, the observed bands are typically at 17-24 kDa

For optimal results, samples should be prepared fresh, and protein degradation should be minimized by keeping samples cold and using protease inhibitors during lysis. The discrepancy between predicted and observed band sizes is likely due to proteolytic processing of MUC1, which is common for membrane glycoproteins.

How can immunoprecipitation with MUC1 antibody be optimized for protein interaction studies?

The MUC1 antibody [EPR1023] (ab109185) has been successfully used for immunoprecipitation of MUC1 protein, particularly from T47-D cells . To optimize immunoprecipitation for protein interaction studies:

• Antibody concentration: Use the purified form of the antibody at approximately 1/20 dilution

• Cell type selection: T47-D cells have been confirmed to work well, but other MUC1-expressing cell lines may also be suitable

• Lysis conditions: Use a lysis buffer that preserves protein-protein interactions (typically containing 1% NP-40 or similar non-ionic detergent, with lower salt concentrations than used for Western blotting)

• Controls: Always include a negative control (PBS or non-specific IgG) to identify non-specific binding

• Detection method: For Western blotting of immunoprecipitated proteins, a HRP-conjugated anti-rabbit IgG specific to the non-reduced form of IgG at 1/1500 dilution has been effective

• Cross-linking considerations: For weak or transient interactions, consider using a cross-linking approach prior to lysis

To detect novel MUC1-interacting proteins, the immunoprecipitated material can be analyzed by mass spectrometry or by Western blotting with antibodies against suspected interaction partners.

What controls should be included when using the MUC1 antibody in immunohistochemistry?

When using the MUC1 antibody for immunohistochemistry on paraffin-embedded sections (IHC-P), the following controls should be included to ensure reliable and interpretable results:

• Positive tissue control: A known MUC1-expressing tissue such as colon cancer samples, which have been shown to work well with this antibody

• Negative tissue control: Tissues known not to express MUC1 or, ideally, MUC1 knockout tissues

• Primary antibody omission control: Sample treated with all reagents except the primary antibody to assess background staining from the secondary detection system

• Isotype control: Irrelevant antibody of the same isotype and concentration as the MUC1 antibody to identify non-specific binding

• Absorption control: Pre-incubation of the antibody with the purified MUC1 antigen to confirm specificity

• Technical replicate sections: Multiple sections from the same sample to confirm staining pattern reproducibility

Appropriate blocking steps should be employed to minimize background, and standardized protocols should be followed to ensure consistent staining intensity for comparative studies. Documentation of specific staining patterns (membrane vs. cytoplasmic vs. nuclear) is important for MUC1, as its localization can vary depending on cancer type and progression.

How can the MUC1 antibody be incorporated into Design of Experiments (DOE) methodology for optimizing immunoassays?

Design of Experiments (DOE) methodology can significantly improve the optimization of immunoassays using antibodies like the MUC1 antibody. Drawing from the monoclonal antibody purification example in the search results, similar principles can be applied to immunoassay development:

• Factor identification: Key factors that might affect assay performance include:

  • Antibody concentration (primary and secondary)

  • Incubation time and temperature

  • Blocking buffer composition

  • Washing stringency

  • Sample preparation method

  • Detection system parameters

• Experimental design: Rather than traditional one-factor-at-a-time (OFAT) optimization, a multifactor DOE approach allows simultaneous assessment of multiple parameters. For example, a custom design with 27 runs (similar to the mAb purification example) could explore 4 factors at 2-3 levels each .

• Response measurements: Key responses to optimize might include:

  • Signal-to-noise ratio

  • Limit of detection

  • Linear dynamic range

  • Coefficient of variation

  • Specificity (cross-reactivity)

• Statistical analysis: Using software like Design-Expert®, responses can be modeled to determine main effects and interactions between factors .

This approach can reduce the optimization time from months to weeks while providing a more comprehensive understanding of the assay performance landscape. The statistical rigor of DOE also provides greater confidence in the optimal conditions identified.

How do different epitope binding regions affect the neutralization potential of monoclonal antibodies in viral research?

While the MUC1 antibody is not a virus-neutralizing antibody, principles from SARS-CoV antibody research can inform our understanding of epitope-function relationships for other antibodies. Research has shown that antibodies recognizing different epitopes on viral proteins can have distinct functional effects despite similar binding affinities.

In SARS-CoV research, two monoclonal antibodies (MAbs 201 and 68) recognized different epitopes on the spike (S) glycoprotein:

• MAb 201: Bound within the receptor-binding domain (aa 490-510) and directly blocked virus binding to the ACE2 receptor

• MAb 68: Bound external to the receptor-binding domain (aa 130-150) and did not block virus binding to cells, yet still neutralized the virus through a different mechanism

Despite these mechanistic differences, both antibodies protected mice from SARS-CoV challenge, with the reduction of virus titers being dose-dependent .

This demonstrates that antibodies can neutralize pathogens through multiple mechanisms:

• Direct blocking of receptor binding

• Interference with conformational changes required for membrane fusion

• Alterations in physical properties (e.g., aggregation)

• Interference with secondary receptor interactions

When developing or selecting antibodies for research, understanding the epitope-function relationship is crucial, as antibodies to different regions may have distinct functional effects despite similar binding properties.

What approaches can resolve discrepancies between predicted and observed molecular weights in MUC1 antibody Western blots?

The MUC1 antibody [EPR1023] (ab109185) detects bands at 17-24 kDa despite the predicted molecular weight of MUC1 being 122 kDa . This discrepancy is common with membrane glycoproteins like MUC1 and requires careful investigation. To resolve such discrepancies:

• Glycosylation analysis:

  • Treat samples with glycosidases (PNGase F for N-linked or O-glycosidase for O-linked glycans)

  • Compare molecular weights before and after treatment

  • Use gradient gels to better resolve high molecular weight glycoforms

• Proteolytic processing investigation:

  • Use antibodies targeting different domains (N-terminal vs. C-terminal)

  • Employ protease inhibitor cocktails during sample preparation

  • Analyze conditioned media for shed extracellular domains

• Expression system considerations:

  • Compare the same protein expressed in different cell types

  • Use cell-free expression systems to obtain unmodified protein standards

  • Co-express with specific processing enzymes to study their effects

• Technical validation approaches:

  • Run parallel Western blots with different antibodies against the same target

  • Confirm identity through immunoprecipitation followed by mass spectrometry

  • Use recombinant fragments of known size as molecular weight markers

• Data interpretation framework:

  Observation	Possible Explanation	Validation Approach
  Multiple bands	Alternative splicing	RT-PCR for transcript variants
  Diffuse bands	Heterogeneous glycosylation	Glycosidase treatment
  Lower than predicted MW	Proteolytic processing	N- vs C-terminal antibodies
  Higher than predicted MW	Post-translational modifications	Specific enzyme treatments
  Cell-type specific patterns	Differential processing machinery	Compare multiple cell lines

Understanding these molecular weight variations is not merely a technical consideration but can provide valuable biological insights into protein processing and regulation in different cellular contexts.

What strategies can resolve non-specific binding issues with MUC1 antibody in immunohistochemistry?

When encountering non-specific binding with the MUC1 antibody in immunohistochemistry, several strategies can be employed:

• Optimization of blocking conditions:

  • Extend blocking time (up to 2 hours)

  • Test alternative blocking agents (BSA, normal serum, commercial blockers)

  • Use dual blocking approach (protein block followed by peroxidase block)

• Antibody dilution optimization:

  • Perform titration series to identify optimal concentration

  • Consider using antibody diluents with background-reducing components

• Washing optimization:

  • Increase number and duration of wash steps

  • Test higher detergent concentration in wash buffers (0.1-0.3% Tween-20)

  • Consider using high-salt wash buffers for highly charged tissues

• Antigen retrieval adjustment:

  • Compare heat-induced epitope retrieval methods (citrate vs. EDTA buffers)

  • Optimize retrieval duration and temperature

  • Test enzymatic retrieval alternatives

• Detection system considerations:

  • Switch to more specific detection systems (polymer-based vs. ABC method)

  • Use species-specific secondary antibodies with minimal cross-reactivity

  • Consider fluorescent detection for tissues with high endogenous peroxidase

If non-specific nuclear staining is observed, additional pre-treatments with nucleases might be beneficial. For tissues with high endogenous biotin, avidin-biotin blocking steps or non-biotin detection systems should be employed.

How can immunoprecipitation-mass spectrometry (IP-MS) workflows be optimized for MUC1 protein complexes?

To optimize immunoprecipitation-mass spectrometry (IP-MS) workflows for MUC1 protein complexes:

• Sample preparation optimization:

  • Use mild lysis conditions to preserve protein interactions (e.g., 1% NP-40 or digitonin)

  • Include protease and phosphatase inhibitors to prevent degradation and maintain modification states

  • Perform lysis at 4°C with minimal mechanical disruption

• IP strategy selection:

  • Direct IP using the MUC1 antibody [EPR1023] (ab109185) at 1/20 dilution

  • Consider crosslinking the antibody to beads to prevent antibody contamination in the eluate

  • For transient interactions, employ in vivo crosslinking prior to lysis

• Controls and specificity verification:

  • Include IgG control IPs from the same species as the primary antibody

  • When possible, perform parallel IPs from MUC1 knockout cells to identify non-specific interactors

  • Use sequential IPs (re-immunoprecipitation) for higher confidence in complex composition

• Elution and MS sample preparation:

  • Test multiple elution conditions (acid, competitive, denaturing) to maximize recovery

  • Consider on-bead digestion to minimize sample loss

  • For glycosylated proteins like MUC1, enzymatic deglycosylation prior to MS analysis may improve peptide identification

• MS data analysis considerations:

  • Apply appropriate statistical filters to distinguish true interactors from background

  • Normalize against IgG control and/or knockout samples

  • Consider interaction dynamics by comparing different cellular conditions

Given the complex glycosylation pattern of MUC1, special attention should be paid to the identification of glycopeptides, potentially employing glycoproteomics approaches for comprehensive characterization.

What are the critical parameters for optimizing flow cytometry protocols with the MUC1 antibody?

The MUC1 antibody [EPR1023] (ab109185) has been validated for intracellular flow cytometry . To optimize flow cytometry protocols with this antibody:

• Fixation and permeabilization optimization:

  • Compare different fixatives (paraformaldehyde, methanol, acetone)

  • Test multiple permeabilization reagents (saponin, Triton X-100, commercial kits)

  • Optimize fixation time and temperature for epitope preservation

• Antibody concentration and staining conditions:

  • Perform titration to determine optimal antibody concentration

  • Optimize staining time (typically 30-60 minutes) and temperature

  • Include proper blocking to reduce non-specific binding

• Buffer composition considerations:

  • Test different buffer systems (PBS vs. HBSS)

  • Optimize protein concentration in staining buffer (0.5-5% BSA or FBS)

  • Consider adding sodium azide to prevent internalization

• Controls for accurate interpretation:

  • Fluorescence Minus One (FMO) controls

  • Isotype controls at the same concentration as the primary antibody

  • Positive controls (cell lines with known MUC1 expression)

  • Negative controls (MUC1 knockout cells if available)

• Multiparameter considerations:

  • Choose compatible fluorophores to minimize spectral overlap

  • Include lineage markers to identify specific cell populations

  • Consider viability dyes to exclude dead cells from analysis

• Instrument settings optimization:

  • Perform proper compensation for multicolor experiments

  • Adjust PMT voltages for optimal signal resolution

  • Use standardized beads for day-to-day calibration

Given that MUC1 is primarily a cell surface glycoprotein but can also be found intracellularly, protocols for both surface and intracellular staining may need to be developed and compared to fully characterize MUC1 expression patterns in different cell types and experimental conditions.

How does antibody affinity and specificity compare between monoclonal and polyclonal antibodies against MUC1?

While the search results focus primarily on monoclonal antibodies like the MUC1 antibody [EPR1023] (ab109185), understanding the comparative advantages of monoclonal versus polyclonal approaches is important for experimental design:

Monoclonal Antibodies (like ab109185):

• Specificity: Recognize a single epitope with high specificity, reducing cross-reactivity

• Batch consistency: Being derived from a single B-cell clone, they provide consistent performance across batches

• Applications: Particularly valuable for applications requiring high specificity such as therapeutic applications, targeted epitope studies, and standardized assays

• Epitope coverage: Limited to a single epitope, which may be masked in certain conditions

Polyclonal Antibodies:

• Epitope recognition: Recognize multiple epitopes on the target protein, potentially increasing sensitivity

• Robustness to protein modifications: Less affected by single amino acid changes or post-translational modifications

• Applications: Often preferred for applications like immunoprecipitation where capturing all forms of the protein is desirable

• Batch variation: May show batch-to-batch variability due to differences in animal immune responses

The recombinant rabbit monoclonal MUC1 antibody [EPR1023] (ab109185) combines advantages of both approaches - the specificity of monoclonals with the typically higher affinity of rabbit-derived antibodies. Its recombinant nature also ensures batch consistency superior to traditional hybridoma-derived monoclonals .

For comprehensive MUC1 studies, researchers might consider using both monoclonal and polyclonal antibodies targeting different epitopes to gain a complete understanding of MUC1 expression, localization, and processing.

What strategies enable effective use of MUC1 antibodies for detecting low-abundance targets in heterogeneous samples?

Detecting low-abundance MUC1 in heterogeneous samples presents challenges that can be addressed through several strategies:

• Signal amplification approaches:

  • Tyramide signal amplification (TSA) for immunohistochemistry

  • Polymer-based detection systems with multiple HRP molecules

  • Biotin-streptavidin systems for multi-layer amplification

• Sample enrichment techniques:

  • Cell sorting to isolate relevant populations

  • Laser capture microdissection for tissue heterogeneity

  • Subcellular fractionation to concentrate compartment-specific signals

• Detection optimization:

  • Extended antibody incubation times (overnight at 4°C)

  • Higher antibody concentrations with reduced background (optimized blocking)

  • More sensitive substrates for chemiluminescent detection

• Comparative methodology:

  Technique	Sensitivity Limit	Best For	Limitations
  Standard IHC	~1,000 molecules/cell	Spatial context	Qualitative results
  Flow cytometry	~100-500 molecules/cell	Single-cell analysis	Loss of tissue context
  Western blot	~50,000 molecules/total lysate	Molecular weight confirmation	No spatial information
  ELISA	~10-100 pg/ml	Quantification	No spatial or size information
  PCR (mRNA)	~10-50 copies/reaction	Transcript detection	Post-transcriptional regulation

• Validation of low-abundance signals:

  • Correlation with orthogonal methods (RNA-seq, proteomics)

  • Biological validation (functional consequences of expression)

  • Comparison across multiple antibodies targeting different epitopes

For heterogeneous tissues like tumors, combining the MUC1 antibody with markers for specific cell types in multiplexed immunofluorescence can provide context for interpreting low-level expression patterns.

How does the neutralization mechanism of antibodies targeting different epitopes inform therapeutic antibody development?

Drawing from the SARS-CoV antibody research, important principles emerge that apply to therapeutic antibody development more broadly:

• Epitope-function relationships:
  The SARS-CoV study demonstrated that antibodies binding different epitopes (MAb 201 to aa 490-510 and MAb 68 to aa 130-150) had distinct mechanisms of action:

  • Direct receptor binding inhibition (MAb 201)

  • Post-binding neutralization through conformational interference (MAb 68)

  This illustrates that effective neutralization can occur through multiple mechanisms, even when the antibody does not block the primary receptor interaction.

• Structure-guided epitope selection:

  • Targeting conserved epitopes minimizes escape mutations

  • Rational selection based on structural understanding improves efficacy

  • Combining antibodies targeting non-overlapping epitopes can enhance potency and reduce escape

• From in vitro neutralization to in vivo protection:
  The SARS-CoV antibodies demonstrated that in vitro neutralization correlates with in vivo protection, with both antibodies showing dose-dependent reduction of virus titers in mouse models .

  Importantly, the protection showed different patterns in different tissues:

  • Complete protection in lung tissues (>10^6-fold reduction)

  • Partial protection in nasal turbinate tissues (upper respiratory tract)

  This tissue-specific protection pattern informs dosing strategies and expectations for therapeutic applications.

• Translation to human applications:
  The SARS-CoV study noted that at doses of 15 mg/kg, antibodies like Palivizumab provide effective prophylaxis against RSV infection in humans, suggesting similar dosing might be effective for SARS-CoV-neutralizing antibodies .

  This cross-application of dosing principles shows how studies with one antibody can inform development of others, even across different targets.

For MUC1-targeting therapeutic antibodies, these principles suggest:

• Epitope mapping is crucial for understanding mechanism of action

• Multiple mechanisms of action may exist beyond direct blocking

• In vivo models should assess tissue-specific effects

• Dose-response relationships from similar therapeutic antibodies can guide development

How might emerging antibody engineering techniques improve MUC1 antibody performance in research applications?

Several emerging antibody engineering techniques show promise for enhancing MUC1 antibody performance:

• Affinity maturation technologies:

  • Phage display with randomized CDR libraries

  • Yeast surface display for directed evolution

  • Computational design of binding interfaces

  These approaches could enhance the binding affinity of MUC1 antibodies, improving sensitivity for detecting low-level expression.

• Format diversification:

  • Single-chain variable fragments (scFvs) for improved tissue penetration

  • Nanobodies (VHH fragments) for accessing sterically hindered epitopes

  • Bispecific formats for simultaneous targeting of MUC1 and other markers

• Conjugation technologies:

  • Site-specific conjugation for homogeneous antibody-drug conjugates

  • Click chemistry for modular functionalization

  • Protein engineering for direct fusion to reporters or functional domains

• Stability engineering:

  • CDR grafting to improve thermostability

  • Disulfide engineering for improved pH and protease resistance

  • Surface charge optimization for reduced aggregation

• Production and purification advances:

  • Leveraging DOE methodology, as demonstrated with monoclonal antibody purification, to optimize antibody production parameters

  • New chromatographic resins that remove process- and product-related contaminants

  • Single-use, disposable technologies that streamline purification while maintaining high selectivity

For the MUC1 antibody specifically, engineering approaches that improve detection of various glycoforms and processed variants would be particularly valuable, given the heterogeneous nature of this heavily glycosylated protein.

What research questions remain unresolved regarding the relationship between MUC1 epitope recognition and biological function?

Despite extensive research on MUC1, several important questions remain unresolved regarding epitope recognition and biological function:

• Glycoform-specific epitope recognition:

  • How do different glycosylation patterns mask or expose antibody epitopes?

  • Can antibodies be developed that specifically recognize disease-associated glycoforms?

  • What is the relationship between epitope accessibility and MUC1 function in different tissues?

• Cleavage-specific recognition:

  • How does proteolytic processing of MUC1 affect antibody binding?

  • Can antibodies specifically recognize cleavage products to monitor MUC1 processing?

  • What is the functional significance of the 17-24 kDa fragments recognized by ab109185 ?

• Subcellular localization dynamics:

  • How does epitope accessibility change with MUC1 trafficking?

  • What conformational changes occur during internalization and recycling?

  • Can antibodies be developed that specifically recognize different conformational states?

• Interaction partner influence:

  • How do protein-protein interactions affect antibody epitope accessibility?

  • Can antibodies be designed to specifically disrupt functional interactions?

  • What structural changes occur in MUC1 upon binding to its various partners?

• Therapeutic targeting considerations:

  • Which epitopes are most effective for inducing antibody-dependent cellular cytotoxicity?

  • How does epitope selection influence internalization and intracellular delivery?

  • Can antibodies be developed that specifically target cancer-associated forms while sparing normal MUC1?

These questions highlight the need for continued development of epitope-specific antibodies like ab109185 and systematic studies correlating epitope recognition with functional outcomes.

How can multifactor DOE approaches improve antibody validation across diverse experimental conditions?

Design of Experiments (DOE) methodology, as illustrated in the monoclonal antibody purification example , offers powerful approaches for comprehensive antibody validation:

• Systematic validation framework:
  Rather than traditional one-factor-at-a-time validation, DOE allows simultaneous assessment of multiple factors affecting antibody performance:

  • Sample preparation variables (fixation, permeabilization, lysis methods)

  • Experimental conditions (temperature, incubation time, buffer composition)

  • Technical parameters (antibody concentration, detection systems)

  • Biological variables (cell types, treatments, disease states)

• Efficiency and comprehensiveness:
  The mAb purification study demonstrated that DOE reduced a 6-month process to "a fraction of that time" . Similarly, antibody validation could be accelerated while becoming more comprehensive:

  • A full factorial design would require 54 combinations for 4 factors at 2-3 levels

  • An optimized design reduced this to 27 runs while maintaining statistical power

  • Similar optimization could be applied to antibody validation

• Interaction detection:
  DOE specifically identifies interactions between factors that traditional approaches miss:

  • How fixation method interacts with antibody concentration

  • How cell type influences optimal incubation conditions

  • How buffer composition affects detection system performance

• Quantitative optimization:
  DOE provides mathematical models for predicting optimal conditions:

  • Response surface methodology to identify optimal antibody concentration across applications

  • Contour plots to visualize trade-offs between specificity and sensitivity

  • Statistical confidence intervals for performance expectations

• Standardized validation framework:

  Factor Category	Examples	Levels to Test	Response Variables
  Sample preparation	Fixation type	3-4 methods	Signal-to-noise ratio
  Technical parameters	Antibody concentration	3-5 dilutions	Specificity (KO validation)
  Experimental conditions	Incubation time	2-3 durations	Reproducibility (CV%)
  Biological variables	Cell/tissue types	3-5 sources	Dynamic range

This approach would transform antibody validation from a qualitative, application-specific process to a quantitative, comprehensive characterization that provides researchers with clear guidelines for optimal use across experimental conditions.